1. 16. Eli Lily and Company and Anthem, Promoting Value Based Payment Arrangements, January 29, 2016, available at (last visited November 9, 2018); See Sexton Ward et al., supra note 14.
2. The High Cost of Prescription Drugs in the United States
3. 6. Staton, T. , “It's Not Just Payers Holding Back on PCSK9 Outcomes Data. Doctors are Holding Back Too,” FiercePharma, February 16, 2016, available at (last visited November 9, 2018).
4. 14. See above Garrison et al., supra note 7; Choe, S. , Learch, C. , “Health Plans Are Actively Exploring Outcomes-Based Contracts,” Avalere Health, May 30, 2017, available at (last visited November 9, 2018); A. Sexton Ward et al., “Regulatory, Legal Uncertainties Are Barriers to Value-Based Agreements for Drugs,” Health Affairs Blog, November 4, 2016, available at (last visited November 9, 2018); P. Keckley, “Value-Based Pricing for Pharmaceuticals: Implications of the Shift From Volume to Value,” Deloitte Issue Brief, 2012, available at (last visited November 9, 2018); P. Neuman, “Risk-Sharing Arrangements that Link Payment for Drugs to Health Outcomes Are Proving Harvard to Implement,” Health Affairs 30, no. 12 (2011): 2329–2337.